Home Health & Wellness Green Tea Compound Could Revolutionise Preeclampsia Treatment, Finds Study

Green Tea Compound Could Revolutionise Preeclampsia Treatment, Finds Study

Reading Time: 2 minutes

Green tea, a beverage enjoyed globally for its taste and health benefits, might hold the key to treating one of the most common and complex complications of pregnancy, preeclampsia. A new study reveals the potential of epigallocatechin-3-gallate (EGCG), a major compound found in green tea, to mitigate the effects of preeclampsia.

Preeclampsia affects approximately 2–8% of pregnant women worldwide and is particularly prevalent in underdeveloped countries. Characterized by hypertension and damage to other organ systems, most notably the liver and kidneys, preeclampsia poses significant risks to both the mother and the unborn child. It has been linked to impaired placental blood flow, leading to a cascade of oxidative stress and inflammation.

EGCG is known for its vasodilator and antioxidant properties. This study focused on the compound’s ability to influence endothelial function, particularly the production of nitric oxide (NO), a key vasodilator whose deficiency is a hallmark of preeclampsia. The research conducted in vitro involved endothelial cells exposed to plasma from both healthy and preeclamptic pregnant women.

The findings were published in the journal Antioxidants.

The study found that EGCG could significantly increase NO production in endothelial cells affected by preeclampsia. This effect was seen to be mediated through the activation of the PI3K/Akt/eNOS pathway, crucial for NO synthesis. Moreover, EGCG enhanced the cells’ antioxidant capacity, an important aspect given the oxidative stress associated with preeclampsia.

An innovative aspect of this research was the incorporation of shear stress, a condition mimicking the force exerted by blood flow in blood vessels, into the experimental model. The findings indicated that EGCG maintained its beneficial effects on NO production and antioxidant response even under these dynamic conditions.

The implications of these findings are significant. EGCG’s ability to restore NO levels and enhance antioxidant responses in endothelial cells presents a promising avenue for the development of novel therapies for preeclampsia. The compound’s accessibility and established safety profile further underscore its potential as a therapeutic agent.

But it is important to note that the study’s in vitro nature and the use of concentrations of EGCG higher than what is typically found in the bloodstream after tea consumption necessitate further research. Clinical trials are essential to validate these findings and ascertain the efficacy and safety of EGCG in treating preeclampsia in pregnant women.

© Copyright 2014–2034 Psychreg Ltd